
Guide for the Assessment of Clotting Factor Concentrates
The purpose of this guide is to inform and facilitate the selection and purchase of therapeutic products for the treatment
Year: 2016
Language: Polish
Author(s): World Federation of Hemophilia
Format: Document
Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese
This is not an official WFH translation. This resource has been translated with permission by a WFH National Member Organization (NMO), and is shared here with their kind permission. Translating organizations are encouraged to have translations reviewed by local experts, the WFH is not responsible for the translation or for any errors or changes to content from the original English edition. Patient organizations interested in translating a WFH resource must first obtain permission from the WFH, available here.
Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than plasma products or recombinant clotting factor concentrates, carries no risk of transmission of viral infections, and is on the World Health Organization’s (WHO) Model List of Essential Medicines (EML).

The purpose of this guide is to inform and facilitate the selection and purchase of therapeutic products for the treatment

A summary of discussions held at the Tenth WFH Global Forum on Research and Treatment Products for Bleeding Disorders which

This illustrated schematic demonstrates the normal process of blood clotting, how it is diminished when a clotting factor is lacking,

In the Tuesday morning medical plenary, Erik Berntorp describes his vision of hemophilia treatment and medical advances in 2030.

This eLearning module presents Section 4 of the WFH Guidelines for the Management of Hemophilia: Hemostatic Agents. Detailed illustrations, interactive